We’ve developed a new approach to CD47 blockade that is designed to maximize clinical activity and minimize toxicities

Our goal is to transform cancer treatment options for patients by developing evorpacept (ALX148) as a foundational checkpoint immunotherapy

Evorpacept Mechanism of Action

ALX Oncology was founded by a team of industry veterans to address fundamental challenges in blocking CD47 and to realize the full potential of this therapeutic target.

Cancer cells employ CD47, a cell surface protein, as a “don’t eat me” signal to evade detection by the immune system. ALX is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches. We believe our lead product candidate, evorpacept (ALX148), will have a wide therapeutic window to block the “don’t eat me” signal on cancer cells, and to leverage the immune activation of broadly used anti-cancer agents through combination strategies. Based on our clinical results to date in multiple oncology indications showing encouraging anti-tumor activity and tolerability, our strategy is to pursue evorpacept as a potentially critical component for future combination treatments in oncology.

Latest News updated at 19:14:21 UTC

May 09, 2022

ALX Oncology Reports First Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights

Apr 12, 2022

ALX Oncology Appoints Itziar Canamasas, Ph.D., to its Board of Directors

Mar 02, 2022

ALX Oncology Announces First Patient Dosed in ASPEN-06, a Phase 2/3 Study of Evorpacept for the Treatment of Patients with Advanced Gastric or Gastroesophageal Junction Cancer

Twitter

ALX Oncology today reported financial results for the first quarter ended March 31, 2022 and provided clinical development and operational highlights: https://bit.ly/3spRQ85

ALX Oncology today announced the appointment of Itziar Canamasas, Ph.D., to its Board of Directors: https://bit.ly/3rjUo7h

We are excited to unveil ALX Oncology's new research facility, located in Palo Alto! To contact ALX Oncology, visit https://bit.ly/3AoWlSp

Load More...

Our Technology

ALX Oncology’s fusion proteins are engineered to bind CD47 with significantly greater affinity than natural SIRPα. Our lead candidate, evorpacept, is an intravenously administered fusion protein containing two engineered high affinity CD47 binding domains of SIRPα linked to an inactive Fc region of human immunoglobulin.

LEARN MORE